| Authors: |
van Meerten T; Department of Haematology, University Medical Center Groningen Groningen, The Netherlands., Kuruvilla J; Princess Margaret Cancer Centre Toronto, ON, Canada., Song KW; Vancouver General Hospital, BC Cancer, The University of British Columbia Vancouver, BC, Canada., Thieblemont C; Assistance Publique-Hôpitaux de Paris, Hemato-Oncology, Hôpital Saint-Louis, Paris University Paris, France., Minnema MC; Department of Haematology, University Medical Center Utrecht Utrecht, The Netherlands., Forcade E; CHU Bordeaux, Service d'Hematologie et Thérapie Cellulaire Bordeaux, France., De Guibert S; Hématologie Clinique, CHU Rennes Rennes, France., Kersten MJ; Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam Amsterdam, The Netherlands., Mutsaers PG; Department of Hematology, Erasmus University Medical Center Rotterdam, The Netherlands., Wermke M; TU Dresden Medizinische Fakultät Carl-Gustav Carus, NCT/UCC Early Clinical Trial Unit/Medizinische Klinik I Dresden, Germany., Zheng Y; Kite, a Gilead Company Santa Monica, CA, USA., Xue A; Kite, a Gilead Company Santa Monica, CA, USA., Winters JN; Kite, a Gilead Company Santa Monica, CA, USA., Nater J; Kite, a Gilead Company Santa Monica, CA, USA., Shen RR; Kite, a Gilead Company Santa Monica, CA, USA., Spooner C; Kite, a Gilead Company Santa Monica, CA, USA., Neumann F; Kite, a Gilead Company Santa Monica, CA, USA., Kim JJ; Kite, a Gilead Company Santa Monica, CA, USA., Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg Würzburg, Germany. |
